Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure (OPTI O2)

Nantes University Hospital (NUH)

Status: Terminated

Conditions: Acute Respiratory Failure

Treatments: Other: Oxygen therapy delivery systems

Study type: Interventional

Funder types: Other

Identifiers

NCT01243918

10/6-D

Details and patient eligibility

About

The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation).12 immunocompetent patients will compare the successive use of oxygen therapy delivery systems Optiflow®/Ospal® and 12 immunodeficient patients will compare the successive use of systems Optiflow®/Non invasive ventilation.

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient hospitalized in the intensive care unit of Nantes University Hospital
• Signed informed consent
• Patient with not hypercapnic acute hypoxemic respiratory failure
• Immunocompetent and immunodeficient patient

Exclusion criteria

• Age < 18 years
• Pregnancy
• Contra-indication to non invasive ventilation
• Allergy to xylocaine
• Coagulation troubles
• Tracheotomized patient
• Urgent indication to intubation
• Hypercapnic acute respiratory failure
• Acute pulmonary edema
• Face or nose malformation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

16 participants in 4 patient groups

VNI/Optiflow, Immunodeficient patients

Experimental group

Description:

VNI = non invasive ventilation

Treatment:

Other: Oxygen therapy delivery systems

Optiflow/VNI, Immunodeficient patients

Experimental group

Description:

VNI = non invasive ventilation

Treatment:

Other: Oxygen therapy delivery systems

Ospal/Optiflow, Immunocompetent patients

Experimental group

Treatment:

Other: Oxygen therapy delivery systems

Optiflow/Ospal, Immunocompetent patients

Experimental group

Treatment:

Other: Oxygen therapy delivery systems